(Q38083112)

28 August 2017

0 references

Once weekly exenatide: efficacy, tolerability and place in therapy (English)

1 reference

28 August 2017

C Wysham

1

1 reference

PubMed ID

23425609

28 August 2017

M Grimm

series ordinal

2

1 reference

PubMed ID

23425609

28 August 2017

S Chen

series ordinal

3

1 reference

28 August 2017

24 March 2013

1 reference

Diabetes, Obesity and Metabolism

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

10

1 reference

28 August 2017

871-881

1 reference

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

28 August 2017

1 reference

The biology of incretin hormones

21 January 2018

1 reference

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

21 January 2018

1 reference

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.

21 January 2018

1 reference

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

21 January 2018

1 reference

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

21 January 2018

1 reference

Biodegradation and biocompatibility of PLA and PLGA microspheres

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

21 January 2018

1 reference

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

21 January 2018

1 reference

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

21 January 2018

1 reference

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations

21 January 2018

1 reference

Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications

21 January 2018

1 reference

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

21 January 2018

1 reference

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

21 January 2018

1 reference

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

Medication taking and diabetes: a systematic review of the literature

21 January 2018

1 reference

Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes.

21 January 2018

1 reference

When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?

21 January 2018

1 reference

The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management

21 January 2018

1 reference

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy

21 January 2018

1 reference

Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes

21 January 2018

1 reference

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12084

1 reference

28 August 2017

1 reference

PubMed ID

23425609